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ABSTRACT 
The aim of the study is to determine whether the 
recommended lab monitoring for metformin is performed 
appropriately in the ambulatory care setting and if the patient 
characteristics are associated with monitoring rate. A cross-sectional 
study was performed using a healthcare claims database. An 
univariate analysis by frequency and percentage assessed the 
characteristics of patients in our study. Also, it measured the 
frequency of lab monitoring: HgbA1C, CBC or B12, SCR, and optimal, 
defined as receiving all three tests. Bivariate analyses determined the 
significance of differences between those receiving and not receiving 
lab testing according to patient characteristics. In a prediction model, 
multivariate logistic modeling with backward elimination was 
performed to identify significant patient characteristics predicting lab 
monitoring, and to obtain adjusted odd ratios. Optimal lab monitoring 
rate during 18 months rate during the 18 month was 32.88 percent. A 
predictive model included age category, cardiovascular, renal, 
respiratory disease, mental health disorder, number of clinic visit, and 
medication possession rate (MPR). Elderly patients with comorbidities 
were more likely to receive optimal care; more frequent clinic visits 
and greater rates of medication adherence were associated with 
receiving optimal lab monitoring for metformin.
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CHAPTER 1 
 
BACKGROUND 
 
Diabetes Mellitus is a global epidemic which affects 8.3% of the 
United States’ population, or 25.8 million in 2010.1 In 1980, the 
number of persons diagnosed with diabetes in America was 5.6 million 
which increased to 20.9 million in 2012.1 Globally, the incidence of 
diabetes is increasing dramatically, caused by more urbanization, 
obesity, and longer-life expectation for patients with diabtes.2 Rising 
number of these patients with diabetes also leads to growing 
expenditure of diabetes care which had become a great burden to the 
American society. From 2002 to 2007, the total cost of diabetes has 
increased from $132 billion to $174 billion.3  
High expenditure is associated with various complications from 
diabetes such as retinopathy, nephropathy, coronary artery disease, 
peripheral artery disease and cerebrovascular disease. Diabetes is the 
leading cause of a kidney failure. In 2008, diabetes was accountable 
for 44% of new cases of a kidney failure.4 About 60 to 70% of 
patients with diabetes have mild to severe forms of nervous system 
damage and they are twice as likely to have depression than people 
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without diabetes.5, 6 In addition to the complications, this population is 
often obese and has a high cholesterol level and blood pressure. 
Therefore, other comorbid, metabolic diseases coexist in patients with 
diabetes; such comorbidities increase the cost of care and complicate 
patients’ drug regimen. Such complex drug regimen and vulnerability 
of patients with diabetes are significant problems for their care.  
According to the current American Diabetic Association (ADA) 
guidelines for diabetes, metformin is a preferred first-line treatment 
for the treatment naïve patients with diabetes type II.7 Metformin use 
is prevalent and its safety and effectiveness has been well 
demonstrated. Hypoglycemia occurs less frequently with metformin 
than any other oral antidiabetic medications. The common side effects 
are diarrhea, flatulence, cobalamine deficiency, and asthenia. Serious 
side effects include lactic acidosis yet this condition is very rare, at 
0.03 cases per 1000 patients years.8, 9, 10 Although metformin is a 
fairly safe drug, laboratory monitoring is recommended to avoid 
anemia, lactic acidosis, or other complications. Vitamin B12 level is 
recommended to be monitored every 2-3 years and hematologic 
parameters should be monitored at the baseline and annually to avoid 
anemia.8,9 Also, renal function test (Serum Creatinine, Scr) before 
initiation and annually thereafter is recommended to monitor the risk 
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of lactic acidosis. Since a substantial amount of metformin is excreted 
through kidney, monitoring Scr level is prudent. Additionally, 
glycosylated hemoglobin (HbA1C) level testing monitors efficacy of 
the drug; it is also a safety measure to monitor hypoglycemia or to 
delay or avoid further complication of diabetes.8, 9 
In practice, however, metformin is often used without safety 
monitoring given its reputation for safety. A retrospective study of 
metformin use in inpatient setting presented that among 204 
hospitalized metformin users, 27% had at least one absolute 
contraindication to metformin.10 The most common contraindication 
was elevated serum creatinine concentration in 32 patients (12%). 
However, metformin was discontinued in only 8 (25%) of these 
patients. The disconnection of clinical guideline for metformin use and 
real practice was found in outpatient setting as well. A cross-sectional 
analysis, conducted in 10 different HMOs, reported that the absence 
of Scr lab testing at the initiation of metformin therapy was 25.8% (95% 
CI 15.2-35.9).11 Also, another cross-sectional study with chronic 
metformin users reported the rate of missing annual Scr testing by 
29%, 26%, 25% in 1999, 2000, 2001, respectively.12 Cell blood count 
testing was missing more frequently, 80%, 79%, 78% in 1999, 2000, 
2001, respectively.  
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Several studies had examined how recommended monitoring is 
practiced in a clinical setting. However, no studies have examined 
metformin users specifically and variables that may be associated with 
suboptimal monitoring. The increasing diabetes population and lower 
safety awareness for metformin necessitates careful assessment of 
metformin safety laboratory screening. Therefore, we conducted this 
study to determine how the practice of laboratory monitoring for 
metformin reflects recommended guidelines. Also, patient 
characteristics that are potentially associated will be identified to 
highlight barriers to those safety measures. We hypothesize that lab 
monitoring for metformin will be suboptimal and may be associated 
with specific patient characteristics. 
 
 
 
 
 
 
 
 
 
  
  
 5  
 
CHAPTER 2 
 
METHODS 
 
 A cross-sectional observational study was performed using a 
claims database from a large commercial insurance plan. Data 
included members with diabetes and described members’ membership 
status, demographic information, medical diagnosis, laboratory testing, 
medication dispensing, and healthcare utilization. The claims data 
included medical utilization data spanning from January 1, 2008 – May 
31, 2010. 
 Inclusion criteria for the study population were a minimum of 
18 years of age, diagnosed with diabetes according to ICD-9 code, 
having 18 months of continuous enrollment, and at least two 
metformin dispensing during the study frame. Also, patients were 
required to have three months before and after the study period to 
capture patients who may receive delayed annual lab monitoring. If 
members were hospitalized during the study period, they were 
excluded because all hospitalized patients would receive lab 
monitoring and therefore the results could be biased.  
We hypothesized that laboratory monitoring for metformin 
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would be suboptimal and would vary according to patient 
characteristics. The main study outcome determined if metformin 
users with diabetes diagnosis received recommended safety lab 
monitoring for metformin. The manufacturer of metformin 
recommends that patients receive at least once yearly monitoring of 
glycosylated hemoglobin (A1C), anemia monitoring which includes 
either cell blood count (CBC) or vitamin B12 (B12) level, and serum 
creatinine level (SCR) which indicates patients’ renal status. Members 
were considered to have optimal safety monitoring if they received all 
of the three lab tests.  
The 2009 Healthcare Effectiveness Data and Information Set 
(HEDIS) standards and Current Procedure Terminology (CPT) codes 
served as a reference for identifying A1C, CBC, B12, and SCR from 
chemistry 7 tests. Common Procedural Terminology (CPT) codes were 
reviewed to identify any hospitalization and the number of clinic visits 
throughout the study period. The International Classification of 
Disease 9 (ICD 9) was used to confirm a diabetes diagnoses for each 
member and to identify comorbidities including cardiovascular disease, 
respiratory disease, mental disease, and renal disease. Cardiovascular 
disease included heart failure, hypertensive heart disease, myocardial 
infarction, angina, and atherosclerosis. Respiratory disease included 
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bronchitis, emphysema, asthma, and chronic obstructive pulmonary 
disease. Mental health disorders included bipolar, paranoid, psychosis, 
autism, personality disorder, depression, conduct disorder and 
attention deficit hyperactivity disorder. Lastly, renal disease included 
hypertensive chronic kidney disease, renovascular hypertension, cystic 
kidney disease, renal dysplasia, kidney transplant, renal dialysis, acute 
kidney failure, and glomerulonephritis.  
 Additionally, the frequencies of A1C, CBC, B12, SCR, and 
optimal lab monitoring performed were stratified into three different 
study periods: 12, 15, and 18 months. The frequency of each lab 
monitoring was to compare the difference among study length and 
allowing additional time of screening. 
 Descriptive statistics of the final cohort included age group, 
gender, diabetes medication use, comorbidities, and level of 
healthcare utilization. Diabetes medication use was classified 
according to the type of metformin product dispensed (sole ingredient 
vs. combination) and by insulin use. The comorbidities were classified 
as cardiovascular, respiratory, mental and renal diseases. Healthcare 
utilization measured five different components: the number of 
prescriptions dispensed during the baseline period (three months 
before the index date), the total cost of medication per month during 
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the screening period, the number of clinic visit and medication 
adherence rate throughout the study period. The frequencies of A1C, 
CBC, B12, SCR, and optimal monitoring performed were also 
measured in the final cohort. Descriptive statistics presented the 
frequencies and percentages for all variables assessed.  
 For these categorical variables, chi-square tests were 
performed to determine statistical significance of differences in 
proportions, according to the optimal lab monitoring outcome 
variables. These categories included age group, gender, types of 
diabetes medication use, comorbidities, and level of healthcare 
utilization. Multi-colinearity between these independent variables was 
examined by a correlation matrix and diagnostics, while the 
interaction among the independent variables was explored using 
multivariate logistic modeling.  
 Predictive models for optimal lab monitoring were built using 
multivariate logistic regression with a backward elimination process. 
All variables were first included and statistically insignificant 
independent variables (P>0.05) were eliminated from the model step 
by step. The Hosmer-Lemshow goodness of fit test assessed the 
validity of the model. The significant independent variables in the 
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model were reported as an adjusted odds ratio with corresponding 95% 
confidence intervals. 
 Data analysis was performed using SAS (version 9.3). 
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CHAPTER 3 
 
RESULTS 
 
A total of 7068 members were selected from 14,908 members 
in the claims database (see flowchart). The sample population had a 
mean age of 63.1 years with a standard deviation of 12.16 (table 1). 
The distribution of age was highest in 40-64 year old group, 57.4 
percent, and was second highest in the 65-79 year old group, 30.74 
percent. The remaining age groups 18-39 year and 80 and older 
contributed 2.45 percent and 9.32 percent of the distribution, 
respectively. The percentages of male and female patients were 54.56 
and 45.44 percent, respectively. A majority of members used 
metformin as a sole ingredient product, 84.80 percent. Only 19.95 
percent of members were using insulin. The cohort members received 
average of 4.8±2.94 prescriptions during three months before the 
study enrollment, and the median cost of the medication per month 
was $20.64. The cohort members visited a doctor’s office an average 
of 10.08±6.19 times throughout the study. The average Medication 
Possession Rate (MPR) was 85.06±20.82 percent.  
During the 18 month study period, the recommended lab 
  
  
 11  
 
monitoring for metformin such as HgbA1C testing, CBC, Vitamin B12, 
and Scr were performed in 75.44, 43.15, 10.98 and 52.57 percent of 
the cohort members. Members who received optimal monitoring 
(HgbA1c, CBC or B12, and Scr) were only 32.88 percent. The percent 
of optimal lab monitoring improved with longer period of assessment: 
12 months 26.1%, 15 months 29.2% and 18 months 32.9% (table 2). 
 In the bivariate analyses, HgbA1C, Anemia Test (CBC or B12), 
Scr, and Optimal tests revealed statistically significant differences 
among age groups (P<0.0001) (table 3). The patients in the oldest 
group were more likely to receive lab monitoring as compared with 
younger patients. Males received less frequent lab testing of any kind 
as compared with females (HgbA1C, Anemia Test, SCR, Optimal, 
respectively, P<0.0001, P<0.0001, P=0.0002, P<0.0001). Insulin-use 
was associated with greater frequency of HgbA1C testing, with 
statistically significant differences as compared to non-insulin-user 
(P=0.0254). Patients with respiratory, cardiovascular, or renal disease 
were more likely to receive any type of lab monitoring performed as 
compared with patients no having these conditions. Unexpectedly, 
patients with mental health disorders had significantly higher number 
of optimal lab performed than patient without mental illnesses 
(p=0.0281). All health utilization components demonstrated 
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statistically significant differences among different categories. A higher 
number of prescriptions and higher cost of medication at baseline and 
higher number of clinic visits were associated with increased lab 
monitoring. Medication adherence was also associated with frequent 
lab monitoring (P<0.0001). Monitoring did not differ according to the 
type of metformin product utilized. 
 The logistic regression model for renal function testing revealed 
that age, cardiovascular disease, renal disease, number of clinic visits, 
and medication adherence were significant in fitting the prediction 
model (table 4). Patients in age category 4 (age 80 and over) were 
approximately four times more likely to receive serum creatinine 
testing as compared with those in age category 2 (40-65 year of age) 
(OR 4.007, 95%CI 3.292-4.877). Cardiovascular disease and renal 
disease also contributed to more frequent lab monitoring for 
metformin than patients with no such comorbidities. Patients with 
more than 14 clinic visits were almost 50 percent more likely to 
receive Scr testing than patients with 7-9 clinic visits (OR 1.489, CI95% 
1.287-1.722). The variable for medication adherence was not 
significant in this analysis, and was thus excluded from the model. 
 The logistic regression model assessing anemia testing which 
reflected either a CBC or B12 test at least once yearly, included 
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gender as a significant independent variable (table 5). Unlike the 
other models, anemia testing was associated with gender. Female 
patients were 15 percent more likely to receive anemia tests than 
male patients (OR 1.151, 95%CI 1.042-1.270). Otherwise, this 
second model was similar to the previous model described above. 
Elderly people and patients with more frequent visit to clinic were also 
more likely to receive lab monitoring for anemia.  
 The model for HgbA1C testing included age, gender, insulin use, 
renal disease, and the number of clinic visits (table 6). The oldest age 
category was eight times more likely to receive HgbA1C testing than 
age category 2 (OR 8.283, 95%CI 5.816-11.797). Among the 
different labs for metformin, HgbA1C testing was most significantly 
associated with older age. HgbA1C testing was also associated with 
insulin use (OR 1.198, 95%CI 1.036-1.384).  
 Finally, the predictive logistic regression model for optimal 
monitoring performed included 7 variables: age group, cardiovascular 
disease, nephropathy, respiratory disease, mental health disorder, 
number of clinic visits, and medication adherence rate (table 7). No 
co-linearity was found between these independent variables, yet there 
was an interaction between category clinic visit3 (10-13) and 
respiratory disease. The interaction term was included in the model 
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originally because of its statistical significance with the outcome 
variable. However, ultimately, it was removed in a backward 
elimination step because the interaction term did not significantly 
affect the logistic model fit.  
 According to the final model, patients in age group of 65-80 
year were 2 times more likely and those 80 year and over were 3 
times more likely to receive optimal lab monitoring for metformin than 
age group of 40-65 year, odd ratios of 2.228 (95% CI 1.983-2.503) 
and 3.204 (95%CI 2.685-3.8230). When patients had other comorbid 
diseases such as cardiovascular disease, renal disease, respiratory 
disease or mental health disorders, such patients were more likely to 
receive optimal lab monitoring for metformin. The odd ratios of 
cardiovascular disease, renal disease, respiratory disease and mental 
disease were 1.190 (95% CI 1.053-1.344), 1.559 (95% CI 1.298-
1.872), 1.205 (95% CI 1.040-1.396), and 1.194 (95% CI 1.030-
1.384), respectively. In assessing level of health utilization, the cohort 
members who visited the clinic less than 6 times throughout a year 
were 23 percent less likely to receive optimal lab monitoring than 
members who visited 7-9 times (OR 0.774, 95%CI 0.667-0.898). The 
members who visited more than 14 times were 94 percent more likely 
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to receive optimal lab monitoring than members who visited 7-9 times 
(OR 1.935, CI95% 1.664-2.250). Lastly, patients who had a 
medication adherence rate of 0-69 percent were less likely to receive 
optimal care than patients who had adherence rate of 80-89 percent 
(OR 0.769, CI95% 0.617-0.957). As expected, higher medication 
adherence rate was associated with a greater frequency of optimal lab 
monitoring. Also, Hosmer and Lemeshow Goodness-of-Fit test 
reported a Chi-square of 6.4535; p=0.5966. There were no 
statistically significant differences between predictive and observed 
value, therefore, confirming the fitness of our modeling. 
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CHAPTER 4 
 
DISCUSSION 
 
 Adverse drug events are unwanted effects from medications 
and many are preventable or treatable. A cohort study of Medicare 
enrollees conducted by Gurwitz JH et al in 2003 examined adverse 
events occurring in the ambulatory setting. The researcher reported 
that 27.6 percent of 1523 adverse drug events were preventable. 
Errors associated with adverse drug events occurred most commonly 
in the monitoring stage (60.8%), which was higher than errors of 
patient adherence (21%) or in prescribing stages (58.4%).14 In 
another study based on a systemic review of adverse medications 
events, Smith DH et al also reported that 21 percent of adverse 
events were preventable, with inadequate monitoring accountable for 
45.4 percent of the drug therapy problems requiring hospital 
admission.15 Monitoring medication therapy is an important aspect of 
the patient care process and it is inadequately performed according to 
current literature.  
This study examined the rate of optimal lab monitoring for 
metformin and attempted to identify the metformin users who are 
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more likely to receive appropriate safety monitoring. We failed to 
reject our stated hypothesis that monitoring in practice is suboptimal 
and associated with patient characteristics. The rate of lab monitoring 
for metformin was less frequent than clinically indicated, and varied 
according to patient characteristics. Only 32.9 percent of patients 
received optimal safety monitoring for metformin. The rate of HgbA1c, 
CBC, B12, and Scr tests, were 75.4%, 43.2%, 11.0%, and 52.6%, 
respectively. The creatinine monitoring rate was lower than previous 
literature has reported.12.13l This difference might be explained by the 
difference in data source, as Hurley et al used data from Health 
Maintenance Organizations (HMOs) having a larger number of 
observations and more complete information about patient care. Also, 
The Rabael et al study only looked at initial monitoring for metformin. 
Ongoing monitoring of metformin is expected to be less than initial 
monitoring. Interestingly, CBC rate was higher in our study members 
than other populations. The result might be caused by higher average 
age of our study patients compared with Hurley et al (63.1 vs. 57.8 
year old).13 
 According to the bivariate analyses, all independent variables 
except type of diabetes medication use and the status of insulin use 
were associated with optimal lab monitoring performed. In addition, 
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multivariate logistic regression modeling revealed that several 
independent variables significantly impacted the performance of 
optimal monitoring. Those variables were age group, comorbidities, 
number of clinic visit and medication adherence rate.  
The older age groups 65-80 year of age and 80 over were 
more likely to receive optimal safety monitoring while younger groups 
40-65 were less likely. Cardiovascular disease, renal disease, mental 
disease, respiratory disease may have brought more attention from 
practitioners and revealed the association with higher possibility of 
optimal lab monitoring performed. In particular, patients with renal 
disease were 50 percent more likely to receive optimal care than 
patient without renal disease (OR 1.559, 95%CI 1.298 and 1.872). 
The group with 14 or more clinic visits was nearly twice as likely to 
receive optimal care as the group having 7-9 clinic visits. The patients 
with lower medication adherence rate than 70 were 23 percent less 
likely to have optimal monitoring than patients with an 80-89 percent 
adherence rate. High medication possession rate may represent high 
health awareness of patients (self-motivated) and be associated with 
more routine clinic visits.  
 Other multivariate models for Scr, CBC or B12, and HgbA1c 
were similarly affected by age, renal disease, and number of clinic 
  
  
 19  
 
visits. Interestingly, gender was a statistically significant variable in 
the models assessing testing for CBC or B12 and HgbA1C. Females 
were more likely to receive an anemia test, given the higher 
prevalence of this condition in female patients. Yet, HgbA1C test 
cannot be explained by different disease prevalence, and it is 
uncertain why females appeared to receive indicated monitoring more 
frequently. 
 Overall, the recommended lab monitoring for metformin was 
not optimally executed in practice. The metformin users with diabetes 
were more likely to receive optimal lab monitoring if they were elderly 
with cardiovascular, renal, respiratory or mental disease, visited the 
clinic more than 14 times in a year and demonstrated a high 
adherence rate with medication. Conversely, healthcare providers 
have to focus on monitoring younger patients with fewer 
comorbidities who do not visit the clinic as often, and having lower 
adherence to medication. Such patients are easiest to be missed in 
care because healthcare encounters are infrequent and typically focus 
on acute medical needs. Recently, pharmacy lab monitoring alert 
systems and other interventions have been explored as a means to 
increase monitoring toward optimizing the safety of care.16 However, a 
first step is for healthcare providers to recognize that metformin lab 
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motoring is suboptimal, and that relatively healthier patients may be 
more likely to miss required laboratory monitoring. Furthermore, it is 
important that providers recognize the importance of lab monitoring 
as an important process to promote safe medication use.  
 Several limitations of this study exist. First, the study was 
conducted in claims database that is specific to one disease state and 
the study period spanned only 18 months. It is not possible to 
generalize our results to larger populations, yet our sample 
represented typical diabetes patients using metformin. Secondly, the 
all-or-none approach to our assessment of optimal lab monitoring 
performed may been overly strict considering typical medical practice. 
Recommended monitoring for metformin may be overly excessive and 
impossible to implement. Third, the study data have particular 
limitations. The claims database was compiled based on the paid 
claims. Therefore, any diagnosis, procedure, and pharmacy data that 
was not recorded or paid out-of-pocket was missed. Also, the results 
could have been biased by patients’ other comorbidities or 
medications that can influence prescribers to order labs. In this study, 
we examined interaction with comorbidities and age to account for 
this bias. 
Some may argue that another limitation to this study is the fact 
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that metformin is considered to be very safe pharmacotherapy. For 
example, several literature has been published that rebukes the 
association of lactic acidosis with metformin use17., 18. However, 
monitoring guidelines and recommendations should ideally match 
practice regardless of the perceived degree of the true risk. In general, 
patients are all at risk of taking medication and usually risks are 
unknown. Therefore, healthcare providers must follow the guidelines 
for safety monitoring to protect their patients, even though it might 
feel unnecessary or ineffective. The roles of government and 
researchers are to make a precise and practical guideline for periodic 
medication safety lab monitoring. Everyone together should make 
every effort to protect patients from harm and prevent unnecessary 
hospitalization and death.  
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TABLES 
Table 1: Characteristics of the Study Sample 
Variable Cohort (n=7068) 
Age, years 
Mean 63.1±12.2 (18 - 99) 
18 - 39  173 (2.45%) 
40 – 64 4063 (57.48%) 
65 – 79 2173 (30.74%) 
80 and more 659 (9.32%) 
Gender 
Male   3856 (54.56%) 
Female 3212 (45.44%) 
Diabetes Medication Use 
Metformin Mono-product  5994 (84.80%) 
Metformin Combination Product 1074 (15.20%) 
Insulin Dependent(Use) 1410 (19.95%) 
Insulin Independent(No Use) 5658 (80.05%) 
Co-morbidity 
Respiratory 981 (13.88%) 
Cardiovascular 1753 (24.80%) 
Mental Health Disorder  1038 (14.69%) 
Nephropathy 568 (8.04%) 
Healthcare Utilization 
Number of Prescriptions at Baseline (Three months period before the index date) 
Mean 4.8±2.94 (1 – 28) 
0 – 2 1636 (23.15%) 
3 1111 (15.72%) 
4 – 5 1928 (27.28%) 
6 – 28 2393 (33.86%) 
Total Cost of Medications Per Month 
Median(Dollar $) 20.64 (0 - 538.83) 
0 – 5.2 1769 (25.03%) 
5.3 – 11.7 1773 (25.08%) 
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Table 1: Characteristics of the Study Sample Continued 
11.8 – 26.7 1769 (25.03%) 
26.8 – 538.8 1757 (24.86%) 
Number of Clinic Visit During the Study Period (During 18 months) 
Mean 10.08±6.19 (0 – 76) 
0 – 6 2201 (31.14%) 
7 – 9 1718 (24.31%) 
10 – 13 1580 (22.35%) 
14- 76  1569 (22.20%) 
Level of Adherence (Medication Possession Rate %) 
Mean 85.06±20.82 (5 – 100%) 
90 – 100 4420 (62.54%) 
80 – 89  547 (7.53%) 
70 – 79 532 (7.63%) 
0 – 69 1569 (22.20%) 
Lab Monitoring(During 18 months) 
A1C 5332 (75.44%) 
CBC 3050 (43.15%) 
B12 776 (10.98%) 
Renal Screening (Scr) 3716 (52.57%) 
Optimal* 2324 (32.88%) 
Optimal* recommend lab monitoring for metformin is to complete HgbA1C, CBC or 
B12, and renal function test (SCR) annually.  
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Table 2: Frequency of Laboratory Monitoring Performed Based According to 12, 15, 
and 18 Month Intervals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 Months 15 Months 18 Months 
Optimal Lab 1841 (26.1%) 2067 (29.2%) 2324 (32.9%) 
HgbA1C 5072 (71.8%) 5201 (73.6%) 5332 (75.4%) 
CBC 2561 (36.2%) 2810 (39.8%) 3050 (43.2%) 
B12 606 (8.6%) 683 (9.7%) 776 (11.0%) 
SCR 3304 (46.8%) 3490 (49.4%) 3716 (52.6%) 
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Table 3: Performance of Recommended Laboratory Monitoring During the 12 Month 
Study Period According to Patient Characteristics.  
Variable Hgb A1C 
testing 
(n=5332) 
CBC or B12 
Testing 
(Anemia Test) 
(n=3233) 
Renal Function 
Test (Scr) 
(n=3716)  
Optimal* 
Monitoring 
Performed 
(n=2324) 
 N (%) N (%) N (%) N (%) 
Age, years 
18-39 121 (2.3%) 65 (2%) 63 (1.7%) 38 (1.6%) 
40-64 2734 (51.3%) 1500 (46.4%) 1715 (46.2%) 981 (42.2%) 
65-79 1852 (34.7%) 1227 (38%) 1431 (38.5%) 952 (41%) 
80 and more 625 (11.7%) 441 (13.6%) 507 (13.6%)   353 (15.2%) 
 P<0.0001 P<0.0001 P<0.0001 P<0.0001 
Gender 
Male 2817 (52.8%) 1649 (51%) 1949 (52.4%) 1191 (51.2%) 
Female 2515 (47.2%) 1584 (49%) 1767 (47.6%) 1133 (48.8%) 
 P<0.0001 P<0.0001 P=0.0002 P<0.0001 
Diabetes Medication Use 
Metformin  
Mono-product  
4517 (84.7%) 2735 (84.6%) 3140 (84.5%) 1957 (84.2%) 
Combination 
product 
815 (15.3%) 498 (15.4%) 576 (15.5%) 367 (15.8%) 
 P=0.7124 P=0.6541 P=0.4516 P=0.3282 
Insulin 
Dependent(Use) 
1096 (20.6%) 
 
645 (20%) 
 
765 (20.6%) 485 (20.9%) 
Independent 
(No Use) 
4236 (79.4%) 2588 (80%) 2951 (79.4%) 1839 (79.1%) 
 P=0.0254 P=0.9978 P=0.1579 P=0.1755 
Co-morbidity* 
Respiratory 768 (14.4%) 515 (16%) 589 (15.9%) 407 (17.5%) 
 
 P=0.0255 P<0.0001 P<0.0001 P<0.0001 
Cardiovascular 1423 (26.7%) 949 (29.4%) 1109 (29.8%) 753 (32.4%) 
 P<0.0001 P<0.0001 P<0.0001 P<0.0001 
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Table 3: Performance of Recommended Laboratory Monitoring During the 12 
Month Study Period According to Patient Characteristics. Continued 
Mental Disease 767 (14.4%) 499 (15.4%) 554 (14.9%) 372 (16%) 
 P=0.2101 P=0.1025 P=0.5778 P=0.0281 
Nephropathy 480 (9%)  351 (10.9%) 386 (10.4%) 279 (12%) 
 P<0.0001 P<0.0001 P<0.0001 P<0.001 
Health Utilization 
Number of Prescriptions at Baseline (Three months period before the index date) 
0 – 2 1199 (22.5%) 679 (21%) 815 (22%) 462 (19.9%) 
3 796 (14.9%) 451 (14%) 541 (14.6%) 314 (13.5%) 
4 – 5 1482 (27.8%) 895 (27.7%) 1013 (27.3%) 640 (27.5%) 
6 – 28 1855 (34.8%) 1208 (37.4%) 1347 (36.2%) 908 (39.1%) 
 P=0.0001 P<0.0001 P<0.0001 P<0.0001 
Total Cost of Medications Per Month  
$0 – 5..2 1250 (23.4%) 722 (22.3%) 838 (22.6%) 497 (21.4%) 
$5.3 – 11.7 1350 (25.3%) 784 (24.2%) 956 (25.7%) 574 (24.7%) 
$11.8 – 26.7 1354 (25.4%) 855 (26.4%) 957 (25.8%) 619 (26.6%) 
$26.8 – 538.8 1378 (25.8%) 872 (27%) 965 (26%) 634 (27.3%) 
 P<0.0001 P<0.0001 P<0.0001 P<0.0001 
Number of Clinic Visit During the Study Period (During 18 months) 
0 – 6 1480 (27.8%) 770 (23.8%) 914 (24.6%) 495 (21.3%) 
7 – 9 1309 (24.5%) 743 (23%) 883 (23.8%) 499 (21.5%) 
10 – 13 1277 (24%) 801 (24.8%) 931 (25.1%) 599 (25.8%) 
14- 76 1266 (23.7%) 919 (28.4%) 988 (26.6%) 731 (31.5%) 
 P<0.0001 P<0.0001 P<0.0001 P<0.0001 
Level of Adherence (Medication Possession Rate %) 
90 – 100 3429 (64.3%) 2111 (65.3%) 2457 (66.1%) 1545 (66.5%) 
80 – 89 395 (7.4%) 252 (7.8%) 274 (7.4%) 185 (8%) 
70 – 79 382 (7.2%) 209 (6.4%) 252 (6.8%) 157(6.8%) 
0 – 69 1126 (21.1%) 661 (20.4%) 733 (19.7%) 437 (18.8%) 
 P<0.0001 P<0.0001 P<0.0001 P<0.0001 
*P-value according to the chi-square test. 
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Table 4: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for SCR 
Testing According to Patient Characteristics 
 Beta Adjusted Odds 
Ratios 
95% CI Low 95% CI High 
Age 
 Cat 1 -0.1891 0.828 0.600 1.141 
Cat 2 N/A N/A   
Cat 3 0.8698 2.386 2.134 2.688 
Cat 4 1.3880 4.007 3.292 4.877 
Comorbidity 
Cardio-Disease 0.1837 1.202 1.065 1.356 
Nephropathy 0.4101 1.507 1.242 1.828 
Health Utilization 
Clinic Visit1 -0.3317 0.718 0.629 0.819 
Clinic Viist2 N/A N/A   
Clinic Visit3 0.2537 1.289 1.117 1.487 
Clinic Viist4 0.3979 1.489 1.287 1.722 
Medication Adherence Level  
MPR1 0.0882 1.092 0.906 1.316 
MPR2 N/A N/A   
MPR3 -0.1003 0.905 0.704 1.161 
MPR4 -0.0848 0.919 0.749 1.127 
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Table 5: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for CBC or 
B12 Testing According to Patient Characteristics 
 Beta Odd Ratios 95% CI Low 95% CI High 
Age 
 Cat 1 0.0104 1.010 0.734 1.391 
 Cat 2 N/A N/A   
Cat 3 0.7276 2.070 1.858 2.306 
Cat 4 1.1387 3.123 2.612 3.733 
Gender 
Female 0.1402 1.151 1.042 1.270 
Comorbidity 
Nephropathy 0.4101 1.507 1.242 1.828 
Health Utilization 
Clinic Visit1 -0.2918 0.747 0.654 0.853 
Clinic Visit2 N/A N/A   
Clinic Visit3 0.2525 1.287 1.118 1.482 
Clinic Visit4 0.5609 1.752 1.519 2.021 
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Table 6: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for HgbA1C 
Testing According to Patient Characteristics 
 Beta Odd Ratios 95% CI Low 95% CI High 
Age 
 Cat 1 0.1077 1.114 0.796 1.558 
 Cat 2  N/A N/A   
Cat 3 0.9795 2.663 2.323 3.054 
Cat 4 2.1142 8.283 5.816 11.797 
Gender 
Female 0.1352 1.145 1.020 1.285 
Insulin Use 
Insulin Use 0.1803 1.198 1.036 1.384 
Comorbidity 
Nephropathy 0.3207 1.378 1.080 1.758 
Health Utilization 
Clinic Visit1 -0.3865 0.679 0.587 0.787 
Clinic Visit2 N/A N/A   
Clinic Visit3 0.2094 1.233 1.038 1.465 
Clinic Visit4 0.1677 1.183 0.995 1.406 
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Table 7: Results of Predictive Logistic Modeling: Adjusted Odds Ratios for Optimal 
Testing According to Patient Characteristics 
 Beta Odd Ratios 95% CI Low 95% CI High 
Age 
Cat 1 -0.0939 0.910 0.625 1.326 
Cat 2 N/A N/A   
Cat 3 0.8010 2.228 1.983 2.503 
Cat 4 1.1644 3.204 2.685 3.823 
Comorbidity 
Cardio-Disease 0.1738 1.190 1.053 1.344 
Nephropathy 0.4439 1.559 1.298 1.872 
Respiratory 0.1865 1.205 1.040 1.396 
Mental Disease 0.1775 1.194 1.030 1.384 
Health Utilization 
Clinic Visit1 -0.2568 0.774 0.667 0.898 
Clinic Visit2 N/A N/A   
Clinic Visit3 0.3430 1.409 1.212 1.638 
Clinic Visit4 0.6602 1.935 1.664 2.250 
Medication Adherence Level  
MPR1 -0.0982 0.906 0.744 1.104 
MPR2 N/A N/A   
MPR3 -0.2077 0.812 0.621 1.063 
MPR4 -0.2633 0.769 0.617 0.957 
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